The story begins in 1969, when Robert Roeder and William Rutter first separated multiple forms of DNA-dependent RNA polymerase from eukaryotic cells. Over the following decades, biochemists painstakingly identified the general transcription factors, TFIID, TFIIB, TFIIE, TFIIF, and TFIIH, that guide polymerase II to promoters and position it precisely at the transcription start site. The TATA box, discovered in histone genes in the late 1970s, became the archetypal promoter element, and the crystal structure of the TATA-box-binding protein bound to DNA in 1993 revealed how this saddle-shaped factor bends the double helix nearly ninety degrees. But these early pictures were static snapshots of isolated parts. What the machinery does as a whole, and how it moves, remained opaque.

Cryo-electron microscopy changed everything. Where X-ray crystallography demanded rigid, homogenous crystals that giant, flexible assemblies rarely form, cryo-EM can capture heterogeneous, dynamic complexes frozen in vitreous ice, and computational classification can sort millions of particle images into distinct conformational states. Structures of the human pre-initiation complex, or PIC, the mega-assembly of polymerase II and general transcription factors on promoter DNA, progressed from low-resolution models to structures resolved at near-atomic detail. In 2021, researchers resolved the polymerase II pre-initiation complex at 2.9 angstroms, revealing the initial stages of DNA opening, and subsequent work captured the PIC in complex with the Mediator co-activator, with TFIIH, and even with the first nucleosome downstream of the promoter.

At the heart of the new understanding is TFIID, a massive 1.2-megadalton complex of the TATA-box-binding protein and thirteen TBP-associated factors, or TAFs. TFIID serves as the primary scaffold for promoter recognition. In its free state, it adopts a compact, autoinhibited conformation in which the lobes that will grip promoter DNA are folded inward. Binding of TBP to the TATA box triggers a dramatic rearrangement, and recent structures show that TFIID engages not only the TATA box but also downstream promoter elements, including the downstream core promoter region, or DPR, discovered through machine-learning analysis of human promoter sequences. Because the majority of human promoters lack a TATA box altogether, these TAF-mediated contacts with downstream DNA are essential for accurate initiation across most of the genome, and different TAF subunits are now known to dictate promoter selectivity and to integrate signals from sequence-specific activator proteins.

Superimposed on this scaffold is Mediator, the thirty-subunit co-activator that physically bridges enhancer-bound transcription factors to the promoter-bound machinery. Structural studies of the complete Mediator-PIC complex, including landmark human structures published in 2021, revealed how Mediator’s head, middle, and tail modules wrap around the polymerase and how its dissociable kinase module can regulate the interaction. The Pol II C-terminal domain, an intrinsically disordered tail of heptad repeats extending from the largest polymerase subunit, threads into the PIC-Mediator assembly, and its phosphorylation by the TFIIH-associated kinase module, through cyclin-dependent kinase 7, marks a critical checkpoint. Serine 5 phosphorylation of the CTD not only helps trigger promoter escape but also recruits the mRNA capping enzyme, coupling the earliest steps of transcription to RNA processing.

Perhaps the most striking theme to emerge from recent structural work is the role of chromatin itself. The +1 nucleosome, the first nucleosome downstream of the transcription start site, is no longer viewed as a mere obstacle. Structures of the +1 nucleosome-bound PIC-Mediator complex show that this histone package acts as a position-dependent regulator, physically orienting the pre-initiation complex, influencing transcription start-site selection, and even enforcing directionality. Epigenetic marks matter here: trimethylation of histone H3 lysine 4 anchors TFIID through the bromodomain of TAF3, while acetylation marks recruit BET-family factors that bridge TFIID and nucleosomes. The nucleosome, in other words, transmits epigenetic information directly into the transcription machinery, helping the PIC integrate genetic sequence and chromatin state into a single decision about where and in which direction to initiate.

The transition from initiation to elongation emerges as a choreographed, programmed process rather than a simple handoff. Before productive synthesis begins, polymerase II must melt the promoter DNA, a task performed primarily by the XPB translocase subunit of TFIIH, which pulls double-stranded DNA into the polymerase cleft to generate torsional stress. Early attempts at synthesis are often abortive: the enzyme repeatedly synthesizes and releases short RNAs of fewer than five nucleotides because the nascent transcript is thermodynamically unstable in the complex. During this phase, the enzyme scrunches downstream DNA into its active site, storing mechanical energy. Structural and single-molecule studies now delineate a three-step mechanism of promoter escape, in which steric pressure from accumulated template DNA and forward translocation of the RNA-DNA hybrid rupture the narrow channel formed by Pol II and TFIIB, causing general transcription factors to dissociate, the transcription bubble to collapse from roughly twenty-one to a stable eleven nucleotides, and the polymerase to commit to elongation, typically after transcribing about eight to twenty-three nucleotides.

Crucially, the review frames transcription initiation as a process governed by surface competition. Each stage of initiation involves factors that bind overlapping or competing surfaces on polymerase II. As CTD phosphorylation proceeds, inhibitory factors are released and regulatory factors are progressively exchanged: Mediator dissociates, DSIF and NELF bind to impose promoter-proximal pausing, and elongation factors await release signals. This model explains how the same binding surfaces can recruit different partners at different times, and how re-initiation, in which scaffold factors remain promoter-bound to launch successive rounds of polymerase loading, can generate the transcriptional bursting observed in single cells. It also rationalizes why paused polymerase can inhibit new initiation, creating feedback loops that shape gene expression dynamics.

The medical implications are substantial. TAF subunits such as TAF1 and TAF10 are required during development but dispensable in certain adult tissues, and PROTAC-mediated degradation of TAF1 has been shown to induce apoptosis in acute myeloid leukemia cells, making components of the initiation machinery emerging drug targets. As cryo-EM continues to push toward imaging these assemblies inside cells, and as single-molecule and nascent-RNA sequencing methods add temporal resolution, the field is converging on a unified view: transcription initiation is not a static lock-and-key event but a dynamic, chromatin-informed, programmed pipeline, and seeing it in atomic detail is finally telling us how life reads its own blueprint.

Subject of Research: Structural and mechanistic basis of transcription initiation by RNA polymerase II in eukaryotes

Article Title: The molecular basis of transcription initiation by RNA polymerase II

Article References: Chen, X., & Xu, Y. (2026). The molecular basis of transcription initiation by RNA polymerase II. Nature Reviews Molecular Cell Biology. https://doi.org/10.1038/s41580-026-01019-2

Image Credits: AI Generated

DOI: 10.1038/s41580-026-01019-2

Keywords: RNA polymerase II, transcription initiation, pre-initiation complex, TFIID, Mediator, cryo-electron microscopy, TATA box, promoter escape, plus-one nucleosome, CTD phosphorylation, TFIIH, gene regulation

For decades, geneticists have relied on the classical genetic code to interpret how DNA sequences translate into proteins. However, a profound mystery persisted: the regulatory framework governing gene expression plasticity remained elusive. While regulatory elements like promoters are known to modulate gene activity, the complex ‘grammar’—or regulatory syntax—that orchestrates precise gene toggling had not been deciphered. This regulatory system is responsible for spatiotemporal gene expression, determining cell identity, behavior, and response to environmental cues.

The urgency of decoding this genomic control system cannot be overstated, especially given that many cancer-related mutations reside in non-coding regions traditionally deemed as “junk DNA.” These mutations often disrupt gene regulation and contribute to tumor development and progression. Historically, interpreting the pathogenic potential of such mutations was a major bottleneck in cancer research. PARM directly addresses this challenge by providing a sophisticated computational tool that can interpret regulatory DNA sequences and predict their effects on gene activity with exceptional accuracy.

The development of PARM was made possible through a collaborative initiative, the PERICODE project, which united seven research groups under the Oncode Institute. Utilizing cutting-edge experimental techniques pioneered in the Bas van Steensel laboratory at the Netherlands Cancer Institute (NKI), researchers employed massively parallel reporter assays (MPRA) to generate millions of quantitative measurements. These experiments systematically tested how myriad short DNA sequences influenced gene expression levels in specific cell types, thereby creating an unprecedented data repository linking promoter architecture to functional output.

Yet, possessing vast data alone is insufficient for biological insight. Here, Jeroen de Ridder’s group at UMC Utrecht harnessed advanced artificial intelligence algorithms to model these experimental results. Unlike conventional AI models that rely on imperfect proxy data, PARM benefited from precisely engineered, high-fidelity datasets explicitly crafted for deciphering gene regulation. This intentional synergy between experimental design and machine learning empowered the creation of an ultra-efficient model fine-tuned for specific cellular environments. By training on meticulously controlled datasets, PARM captures nuanced, cell-type specific regulatory logics that previous models missed.

Demonstrating extraordinary predictive power, PARM elucidates how gene regulation varies not only between cell types but also dynamically changes under environmental stimuli, such as exposure to drugs or hormones. This dynamic modeling revealed the detailed architecture of regulatory elements—effectively exposing each gene’s “on” and “off” control switches and their combinatorial interactions. Importantly, the scientific team subjected every prediction to rigorous experimental validation, assuring the robustness and biological fidelity of the model’s insights.

PARM also innovates through its remarkable computational efficiency. Previous state-of-the-art models, like Google DeepMind’s AlphaGenome, while powerful, demanded colossal computational resources making them less accessible to many research laboratories worldwide. PARM’s architecture requires approximately one thousand times less computing power, making it achievable for typical academic environments. This efficiency was achieved without sacrificing performance, meaning researchers worldwide can now simulate complex regulatory landscapes using modest laboratory setups and conventional computing hardware within a single day.

This breakthrough has profound implications for cancer biology and therapeutic development. By enabling accurate prediction of regulatory mutation impacts in specific cell types and conditions, PARM opens novel avenues for precision oncology, such as designing patient-specific diagnostics and stratified treatments. The ability to forecast how tumor cells may adapt or resist therapeutics at the level of gene regulation provides an invaluable resource for drug discovery and personalized medicine.

The success of PARM underscores the power of multidisciplinary collaboration bridging genomics, computational biology, and experimental biophysics. Funded by notable institutions such as the Oncode Institute and the AVL Foundation, this collective effort amalgamated expertise from Bas van Steensel’s group at NKI, Jeroen de Ridder’s team at UMC Utrecht, and several other leading genomic research labs. Such integration of experimental high-throughput approaches with deep learning signifies a paradigm shift in decoding biological complexity.

Importantly, PARM’s design also bridges the gap between scalability and interpretability, two features often mutually exclusive in AI. By tailoring its predictive models to highly specific cellular states, PARM manages to retain mechanistic interpretability—insight into the regulatory grammar—while scaling analyses across millions of variants. This combination promises to accelerate functional genomics research across a broad spectrum of diseases and biological systems beyond oncology.

Looking forward, the research community anticipates PARM’s versatility to expand substantially. Researchers can now systematically map gene regulatory changes across diverse human tissues, developmental stages, and disease contexts. The model’s adaptability to incorporate different stimulus-response patterns also sets the stage for unraveling how environmental factors and pharmacological agents reshape epigenetic landscapes, further enriching our understanding of gene control in health and disease.

As the frontiers of genomics advance deeper into the realm of regulatory DNA, tools like PARM will be indispensable for translating vast sequence data into actionable biological knowledge. This model not only demystifies how non-coding DNA dictates cellular phenotypes but also empowers a new generation of genomic medicine that integrates predictive, customizable insights into clinical workflows.

In sum, the advent of PARM signifies a scientific milestone: the ability to ‘read’ the language of gene regulation at unparalleled resolution and scale. By transforming gene regulatory decoding from an enigmatic black box into an interpretable and computable framework, PARM promises to accelerate breakthroughs in cancer biology, therapeutic design, and fundamental genomics, heralding a new era of precision in biomedical science.

Subject of Research: Cells

Article Title: Regulatory grammar in human promoters uncovered by MPRA-based deep learning

News Publication Date: 3-Feb-2026

Web References:

• Nature article
• PARM model portal

References:
Bas van Steensel, Jeroen de Ridder, et al. Regulatory grammar in human promoters uncovered by MPRA-based deep learning. Nature, 2026. DOI: 10.1038/s41586-025-10093-z

Image Credits: ©Netherlands Cancer Institute / Sanne Hijlkema

Keywords: Gene expression, Machine learning

Nucleosomes are the fundamental units of chromatin, composed of DNA wrapped around histone proteins. This structure plays a crucial role in regulating gene expression by controlling the accessibility of DNA to transcriptional machinery. The placement and occupancy of nucleosomes can dramatically influence transcription, making the accurate prediction of their positioning a compelling challenge. The advent of models like HDGS-Net could catalyze not only basic genomic research but also applied fields such as synthetic biology and gene therapy.

Researchers Shi, Wang, and Teng, along with their colleagues, have meticulously engineered HDGS-Net to learn directly from high-dimensional genomic data. Utilizing advanced deep learning techniques, the model efficiently captures intricate patterns tied to nucleosome occupancy. By merging dilated convolutions with gated mechanisms, the architecture allows for finer control over information passage, enhancing both the accuracy and computational efficiency of predictions concerning nucleosome placements.

This sophisticated approach emerges from recognizing that traditional models often succumb to limitations due to their inability to factor in long-range dependencies and interactions present in genomic datasets. The hybrid nature of HDGS-Net enables it to consider broader spatial contexts, thereby increasing the model’s predictability across diverse genomic regions. The result stands not only in improved accuracy but also in the model’s generalizability across various organisms, opening doors for extensive comparative genomic studies.

Training the HDGS-Net model involved a comprehensive dataset encompassing a wide array of epigenomic signals, with particular focus placed on features that influence nucleosome positioning. This process engaged both supervised and unsupervised learning strategies, allowing the model to develop a robust understanding of the underlying biological processes. The flexibility of this hybrid architecture significantly enhances its ability to adapt and learn from varying data conditions, promising exceptional outcomes in nucleosome modeling.

Moreover, the researchers conducted robust validation of HDGS-Net, employing several benchmark datasets against which they meticulously compared their predictions. These tests yielded remarkable improvements, showcasing HDGS-Net’s ability to outperform traditional nucleosome prediction methods. Statistical analyses demonstrated that the model could reduce prediction errors significantly while simultaneously enhancing the biological relevance of its outputs.

Beyond its technical merits, the implications of HDGS-Net resonate deeply within the broader scientific community. As researchers grapple with the complexities of genetic regulation and chromatin dynamics, tools that provide clear insights into nucleosome occupancy are invaluable. HDGS-Net stands to not only enrich our understanding of gene regulation but also expedite the discovery of novel therapeutic targets by elucidating epigenetic modifications that influence disease states.

Furthermore, the model’s design encourages future enhancements, allowing for integration with multi-omics data. This capability paves the way for complex models that could incorporate transcriptomic, proteomic, and even metabolomic data, establishing a more holistic view of the genomic landscape. By creating a comprehensive mapping of the epigenetic landscape, researchers can cultivate insights that lead to more precise and personalized medical treatments.

HDGS-Net also carries significant implications for the future of genomic research. As more researchers adopt artificial intelligence and machine learning methodologies, the accumulation of knowledge from tools like HDGS-Net will propel the field forward. By fostering collaborative environments where bioinformaticians, geneticists, and machine learning specialists can interact, the potential for revolutionary discoveries becomes ever more attainable.

Furthermore, the ease of access to such advanced computational tools is crucial for democratizing genomic research. The availability of HDGS-Net’s predictions can potentially bolster research efforts in laboratories worldwide, including those in resource-limited settings. This democratization of technology reinforces the notion that breakthroughs in genetics should not be confined to well-funded institutions.

In the broader context of technological advancement, HDGS-Net epitomizes how artificial intelligence can yield significant strides in specialized scientific fields. It serves to bridge the gap between computational techniques and biological inquiry, illustrating the profound potential of interdisciplinary collaboration in driving scientific innovation. As researchers delve deeper into the functionalities of HDGS-Net, a cascade of discoveries across diverse biological disciplines is poised to emerge.

The introduction of HDGS-Net is poised to become a cornerstone in the fields of computational genomics, providing researchers with a powerful tool to explore the complexities of nucleosome occupancy and its implications on gene regulation. As the exploration of genomic interactions continues to unfold, the future looks bright for computational models that harness cutting-edge technologies to unlock the mysteries of the biological world.

In this exciting age of genomic research, HDGS-Net stands as a hallmark of innovation, paving the way for a deeper understanding of the fundamental mechanics governing life at a molecular level. As human capacity to decode genetic information expands, the ramifications of such advancements ripple through medicine, biotechnology, and beyond, shaping the very fabric of future biological discoveries.

As the team behind HDGS-Net continues to refine and disseminate their findings, the scientific community awaits with bated breath at the prospect of further advancements. The true potential of such models lies not only in their capacity to predict nucleosome occupancy but also in their ability to inspire new generations of researchers to explore, innovate, and transform the possibilities innate within genomic science.

Subject of Research: Nucleosome occupancy prediction

Article Title: HDGS-Net: nucleosome occupancy prediction based on a hybrid dilated gated separable convolutional neural network

Article References:

Shi, F., Wang, M., Teng, Z. et al. HDGS-Net: nucleosome occupancy prediction based on a hybrid dilated gated separable convolutional neural network.
BMC Genomics (2026). https://doi.org/10.1186/s12864-026-12523-2

Image Credits: AI Generated

DOI: 10.1186/s12864-026-12523-2

Keywords: Nucleosome occupancy, computational genomics, artificial intelligence, hybrid dilated gated separable convolutional neural network, gene regulation

The csRNA-seq methodology is meticulously designed to start with total RNA, which can be sourced from diverse biological materials, such as fresh, frozen, or fixed cells and tissues, including clinical and pathogenic samples. This flexibility underscores the adaptability of the csRNA-seq protocol, making it a robust tool for researchers in various biological contexts. By focusing specifically on the enrichment of actively initiating 5′-capped RNA polymerase II transcripts, csRNA-seq offers a reliable means of capturing both stable and transient RNA species, which is critical for assessing transcriptional activity.

One of the greatest advantages of the csRNA-seq technique is its ability to encapsulate a comprehensive snapshot of gene expression. This method enables researchers to identify actively transcribed regions within the genome, providing insight into the dynamics of gene regulation at a granular level. The technique allows for the detection of nascent transcripts, which are pivotal in understanding how genes are regulated and expressed in response to various stimuli. This insight is especially valuable for investigating cis-regulatory elements, which are crucial for controlling gene activity.

The detailed protocol for csRNA-seq includes several key steps that are critical for successfully isolating and analyzing small RNAs. Initially, total RNA is extracted from the designated biological samples. Following RNA isolation, the process advances to specifically enriching for 5′-capped RNA molecules through a series of purification steps. These measures ensure that the resultant RNA pool comprises predominantly the actively transcribing RNA species that researchers aim to study.

Once the RNA has been adequately enriched, the process moves to library preparation and sequencing. During this stage, the enriched RNAs are converted into a format suitable for high-throughput sequencing technologies. This transition is crucial as it allows for the detailed analysis of the RNA population, enabling the identification of transcription start sites and the characterization of RNA transcript lengths and structures.

By utilizing high-resolution sequencing data, researchers can obtain precise mappings of transcription initiation events. This capability offers unprecedented insight into the timing and regulation of gene expression, illuminating the way in which different RNA forms contribute to cellular functions. Importantly, this high-level detail aids scientists in associating specific transcription events with broader regulatory networks and biological outcomes.

Moreover, an outstanding feature of the csRNA-seq technique is its scalability. It can be applied to different experimental setups, ranging from small-scale academic research to large clinical studies. This scalability is particularly beneficial in translational research, where the accessibility of comprehensive and high-quality transcriptomic data is vital for developing therapeutic strategies and understanding disease mechanisms.

Importantly, the csRNA-seq protocol’s safety profile is noteworthy, as purified RNA can be derived from inactivated samples, allowing for the safe handling and transport of clinical materials. This aspect is particularly relevant in contexts involving biological materials that may be classified as hazardous, ensuring that research can continue under standard laboratory conditions without compromising researcher safety.

The versatility of csRNA-seq extends beyond its methodological merits; it empowers researchers with varying levels of experience in transcriptomics. The user-friendly nature of the protocol streamlines the workflows involved in studying gene regulation and transcription dynamics. This accessibility allows a broader range of scientists, including those new to the field, to engage in impactful research that could lead to significant discoveries.

Furthermore, the implications of this research extend to a more profound understanding of transcriptional programs that are pivotal in development, differentiation, and various disease states. By facilitating the exploration of regulatory elements controlling gene expression, csRNA-seq may enable breakthroughs in personalized medicine, where individual genetic backgrounds and expressions can be accounted for when designing therapeutic approaches.

The insights garnered from employing csRNA-seq are instrumental in broadening our understanding of the functional roles of RNA in the cellular landscape. As we continue to unveil the complexities of gene regulation and transcription mechanisms, such novel methodologies will serve as foundational tools, paving the way for future discoveries in molecular biology and genetics.

In conclusion, the advent of capped small RNA sequencing (csRNA-seq) represents a significant milestone in the realm of transcriptomics. This innovative methodology not only enhances our capacity to profile active RNA polymerase II transcription initiation but also illuminates the dynamic interplay of RNA species within the cellular context. Given its broad applicability and robust design, csRNA-seq holds great promise for advancing our understanding of gene regulation and the multifaceted roles of RNA in biological systems.

Subject of Research: Profiling active RNA polymerase II transcription initiation through capped small RNA sequencing (csRNA-seq).

Article Title: Profiling active RNA polymerase II transcription start sites from total RNA by capped small RNA sequencing (csRNA-seq).

Article References: Meyer, M.K., Olanrewaju, O.J., Montilla-Perez, P. et al. Profiling active RNA polymerase II transcription start sites from total RNA by capped small RNA sequencing (csRNA-seq). Nat Protoc (2026). https://doi.org/10.1038/s41596-025-01285-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41596-025-01285-y

Keywords: RNA sequencing, transcription regulation, gene expression, non-coding RNA, enhancer RNA, csRNA-seq, RNA polymerase II, cis-regulatory elements.

MicroRNAs function as post-transcriptional regulators that fine-tune gene expression by binding to target messenger RNAs, typically resulting in degradation or translational repression. In cancer, this delicate balance is frequently disrupted, leading to aberrant miRNA expression profiles. Some miRNAs act as tumor suppressors, inhibiting pathways critical for cellular proliferation and survival. Conversely, others function as oncogenes, or “oncomiRs,” promoting oncogenic signaling networks. The dualistic nature of miRNAs emphasizes their context-dependent functions—an intricate characteristic that complicates therapeutic targeting but simultaneously offers specificity in modulating cancerous processes.

Extensive profiling of miRNA dysregulation across various tumor types has revealed specific signatures correlating with disease subtypes, stages, and prognosis. These findings underpin the burgeoning interest in employing miRNAs as biomarkers for cancer diagnosis, prognosis, and therapeutic response monitoring. Unlike traditional protein markers, miRNAs are remarkably stable in biofluids, such as blood and saliva, enabling non-invasive liquid biopsy approaches. Researchers have capitalized on this stability to develop miRNA-based molecular tests, some of which have already reached clinical trial phases, suggesting imminent integration into routine oncological practice.

Yet, translating miRNA research into clinical tools has not been without challenges. The heterogeneity of tumors, coupled with the multifactorial roles of individual miRNAs, demands sophisticated analytical frameworks. This is where the advent of artificial intelligence and machine learning has revolutionized the field. By leveraging AI algorithms, researchers can integrate vast, multidimensional datasets including genomics, transcriptomics, and epigenomics, to uncover subtle patterns and interactions that would elude conventional statistical methods. These computational approaches have dramatically enhanced the accuracy of miRNA biomarker identification and patient stratification strategies.

AI-driven platforms facilitate the identification of miRNA signatures not only associated with cancer presence but also predictive of treatment resistance and relapse. Such insights enable oncologists to tailor therapies based on an individual’s molecular profile, marking a step toward truly personalized medicine. Moreover, AI algorithms aid in the rational design of miRNA-based therapeutics by modeling target interactions and optimizing delivery systems, addressing previous bottlenecks related to off-target effects and bioavailability.

The integration of miRNA-based diagnostics and therapeutics is also spearheading combinatorial treatment approaches. By modulating miRNAs that regulate drug sensitivity pathways, researchers have demonstrated enhanced efficacy of conventional chemotherapies and targeted agents in preclinical models. This synergy opens avenues to mitigate resistance mechanisms that frequently limit clinical success, underscoring the promise of miRNAs as adjuncts to existing treatment modalities.

Importantly, the review emphasizes the evolving landscape of clinical trials involving miRNA technologies. Several ongoing studies investigate miRNA mimics or inhibitors as standalone or combinatorial agents, evaluating their safety and efficacy across various cancer types. Concurrently, trials deploying AI-guided biomarker panels aim to refine patient selection criteria, optimize dosing, and monitor treatment response in real time. This convergence of molecular biology and computational science is redefining clinical oncology paradigms.

Behind these advancements lies a convergence of multidisciplinary collaboration, with bioinformaticians, molecular biologists, clinicians, and data scientists contributing their expertise. The interdisciplinary nature of this research sphere is pivotal to overcoming existing hurdles and expediting the bench-to-bedside transition of miRNA applications. Moreover, ethical considerations regarding data privacy, algorithmic transparency, and regulatory approval pathways are being actively addressed to ensure responsible implementation.

Looking forward, the authors highlight emerging opportunities that promise to further accelerate miRNA translational success. Advances in single-cell sequencing and spatial transcriptomics promise unprecedented resolution in decoding miRNA functions within tumor microenvironments. Coupled with AI’s analytical prowess, these technologies will elucidate complex cell-cell communication networks and highlight novel therapeutic targets.

Simultaneously, the refinement of delivery platforms, such as nanoparticle-based vectors and exosome engineering, is overcoming historic challenges related to specificity and immunogenicity of miRNA therapeutics. These developments are vital to realizing the full clinical potential of miRNAs, transforming them from molecular curiosities into mainstays of cancer management.

Despite these promising strides, uncertainties remain regarding standardized protocols for miRNA biomarker validation and therapeutic administration. The review articulates the necessity of large-scale, multicenter validation studies and harmonized guidelines to ensure reproducibility and clinical applicability. It also underscores the importance of fostering collaboration between academia, industry, and regulatory bodies.

In conclusion, microRNAs have evolved from obscure regulatory molecules into powerful biomarkers and therapeutic agents with transformative potential in oncology. Enabled by the synergistic integration of artificial intelligence, molecular biology is entering a new epoch where comprehensive, data-driven insights catalyze precision cancer care. The visionary synthesis presented by Jurj and colleagues not only charts the current landscape but also maps a compelling roadmap for future innovation at the nexus of biology, technology, and medicine.

The dawn of AI-powered miRNA research heralds a paradigm shift—ushering in an era where the once-elusive goal of tailored, effective, and minimally invasive cancer management becomes an attainable reality. As this field matures, continued investment in technology, collaborative frameworks, and patient-centered research will be crucial to transforming these molecular marvels into tangible clinical triumphs.

Subject of Research: MicroRNAs in cancer biology and their translational applications enhanced by artificial intelligence

Article Title: MicroRNAs in oncology: a translational perspective in the era of AI

Article References:
Jurj, A., Dragomir, M.P., Li, Z. et al. MicroRNAs in oncology: a translational perspective in the era of AI. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-025-01114-x

Image Credits: AI Generated

Historically, the core focus in the study of cis-regulatory elements (cCREs) has revolved around enhancers and promoters that activate gene expression. However, the intricacies of silencer elements—regions that actively suppress transcription—have remained elusive, primarily due to the challenges associated with detecting them on a genome-wide scale. This new work leverages an innovative technique known as STARR-seq (self-transcribing active regulatory region sequencing) combined with rigorous computational analyses to chart silencer activity with unprecedented resolution.

The team harnessed negative STARR scores, a novel metric derived from STARR-seq data, to confidently identify silencer activity across the genome. By deploying their specialized tool, CAPRA, they cataloged thousands of silencer cCREs in the widely studied K562 human myelogenous leukemia cell line. The identified silencers included 545 high-confidence (stringent) and 5,468 broader (robust) candidates, revealing a substantial landscape of silencing regulatory elements that extend far beyond the classical REST^+^ (RE1-silencing transcription factor) sites.

Importantly, these newly mapped silencers demonstrated reproducible negative regulatory effects across independent datasets and multiple cell types, underscoring their functional relevance. Their prevalence in non-promoter and non-enhancer genomic regions suggests that the regulatory architecture of gene repression is more diverse and complex than previously appreciated. The researchers propose expanding classification schemes of cCREs to incorporate these findings, highlighting classes such as CA-TF (chromatin-associated transcription factors) as critical for decoding repression mechanisms.

Functional implications were further substantiated by integrating expression analyses, which showed genes adjacent to these silencer cCREs had significantly lower expression levels in K562 cells. These genes were notably enriched for functions in nervous system and renal development, reinforcing the hypothesis that silencers serve as gatekeepers, repressing tissue-specific gene programs outside their native context to maintain cellular identity and prevent inappropriate gene activation.

From a sequence perspective, the study uncovered distinct features among silencers, including a marked enrichment for motifs recognized by the transcriptional repressor GFI1B. This was coupled with ChIP-seq analyses revealing overlapping occupancy by various transcription factors and chromatin remodeling complexes, hinting at a layered regulatory framework orchestrating silencing activity. Contrary to expectations, these silencers did not align with classic repressive chromatin states but instead showed consistent depletion of active histone marks, suggesting silencing may operate through alternative chromatin configurations.

Evolutionary analyses provided compelling evidence for the functional importance of silencers. These elements exhibited greater conservation across mammalian species than non-regulatory genomic regions, albeit less than the well-characterized REST^+^ silencers. Additionally, silencers were enriched in regions overlapping LINE (long interspersed nuclear elements) repeats, hinting at a possible co-evolutionary relationship or functional repurposing of transposable elements in gene regulation.

Beyond genomic and epigenomic characterizations, the functional validation was strengthened by integrating CRISPR interference (CRISPRi) coupled with flow-fluorescence in situ hybridization (FISH), a powerful approach to perturb and visualize regulatory elements in their native chromatin context. Two silencers were directly targeted, including one particularly intriguing cCRE—EH38E4193243—which demonstrated the dual capacity to act as an enhancer in retinal cells and a silencer in K562 cells, mediated by the REST factor.

This dual functionality illustrates the dynamic nature of regulatory elements depending on cellular identity and chromatin context. Importantly, silencing at EH38E4193243 in K562 cells led to increased expression of the upstream gene PRDX2, facilitated through long-range chromatin interactions, highlighting the capacity of silencers to exert distal regulatory impacts beyond their immediate genomic neighborhood.

The findings outlined in this study not only expand the catalog of human cis-regulatory elements but also revolutionize our understanding of the genomic regulatory code underpinning gene silencing. By unveiling the widespread presence and diverse mechanisms of silencers, this work opens new avenues for researching tissue-specific gene repression, epigenetic regulation, and potentially therapeutic targeting in disease contexts where dysregulated gene silencing plays a pivotal role.

As genome biology continues to unravel the complex interplay of activation and repression, delineating the full repertoire and functional nuances of silencers will be essential. This study provides critical methodological innovations and foundational insights that will undoubtedly influence the next wave of genomic and epigenomic research.

In the future, applying similar integrative approaches across various cell types and disease states could illuminate how silencers contribute to cellular differentiation, development, and pathogenesis. Ultimately, understanding silencers in depth promises transformative implications for biotechnology, precision medicine, and synthetic biology, where precise modulation of gene expression is paramount.

This landmark research exemplifies how multilayered genomic, epigenomic, computational, and functional assays can converge to decode the complex gene regulatory networks sustaining life, ensuring that silencers receive their deserved attention in the symphony of genome regulation.

Subject of Research: Gene regulation focusing on cis-regulatory silencer elements and their genome-wide identification and characterization.

Article Title: An expanded registry of candidate cis-regulatory elements.

Article References:
Moore, J.E., Pratt, H.E., Fan, K. et al. An expanded registry of candidate cis-regulatory elements. Nature (2026). https://doi.org/10.1038/s41586-025-09909-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-025-09909-9

Folding of RNA into stable and functional configurations involves complex intramolecular interactions that yield characteristic secondary and tertiary structures. These structures are critical because they dictate RNA’s ability to interact with other biomolecules and execute its biological roles. While experimental methods such as X-ray crystallography and nuclear magnetic resonance can provide snapshots of these structures, they are labor-intensive and sometimes fail to capture dynamic folding processes. Consequently, molecular dynamics (MD) simulations have become a powerful computational tool for investigating RNA folding, enabling researchers to model the movement of atoms over time under defined physical laws.

Despite advances, simulating the full folding process of RNA molecules starting from an unfolded chain to their native conformation remains notoriously difficult. Standard MD simulations require extensive computational resources due to the sheer number of atoms involved and the prolonged timescales needed to observe folding, often beyond what is feasible with explicit solvent models where every water molecule and ion is individually represented. This limitation has historically confined successful folding simulations to small, simple RNA motifs, typically short stem-loop structures comprising approximately ten nucleotides.

In this groundbreaking research spearheaded by Associate Professor Tadashi Ando at Tokyo University of Science, Japan, a paradigm shift in RNA folding simulations has been achieved. The study employed a hybrid computational approach, combining an advanced atomistic force field named DESRES-RNA, which meticulously represents atomic interactions in RNA molecules, with the GB-neck2 generalized Born implicit solvent model. This solvent model abstracts the aqueous environment as a continuous medium rather than discrete molecules, significantly accelerating the conformational sampling process without substantial compromise in accuracy.

Dr. Ando’s team applied this innovative computational framework to an unprecedentedly diverse library of 26 RNA stem-loop constructs. These molecules varied broadly in size, from 10 to 36 nucleotides, and included structural features such as bulges and internal loops which add complexity to folding dynamics. Importantly, all simulations initiated from fully extended, unfolded configurations, simulating the entire trajectory of folding rather than shortcuts from partially folded states. This rigor provided a stringent test of the model’s predictive power.

The results were remarkably encouraging: 23 out of 26 RNA molecules folded into their experimentally determined native-like conformations. The fidelity of these folds was quantified using root mean square deviation (RMSD) metrics comparing simulation outcomes to known structures. For the simpler stem-loop RNAs, RMSD values were impressively low, under 2 angstroms for the stem regions, and remained below 5 angstroms over the full molecule, signaling high structural accuracy. These findings demonstrate that the integrated DESRES-RNA force field and GB-neck2 solvent approach can reliably replicate the native folding pathways of structurally diverse RNA sequences.

The study also tackled more challenging RNA motifs featuring bulges and internal loops, common in functional RNAs such as ribozymes and riboswitches. Of the eight complex structures studied, five reached their correct fold, an achievement that surpasses previous MD simulation capabilities for such systems. The simulations also unveiled distinct folding pathways unique to these motifs, offering unprecedented insights into the mechanistic routes RNA molecules traverse during folding.

While largely successful, the research highlighted areas needing further refinement. Particularly, the loop regions of the RNA molecules exhibited somewhat less precision with RMSD values nearing 4 angstroms, indicating room for improvement in modeling non-canonical base pairing and the nuanced electrostatic environment. Additionally, the implicit solvent model presently overlooks critical effects of divalent cations like magnesium ions, which substantially stabilize RNA tertiary structures and influence folding kinetics. Optimizing the interaction parameters for these ions and loop dynamics could enhance simulation fidelity further.

The significance of this achievement stretches beyond academic interest. Reliable RNA folding simulations pave the way for rational design of RNA molecules for therapeutic and biotechnological applications. For instance, understanding the folding process aids in developing RNA-targeting drugs capable of combating viral infections such as COVID-19 and influenza, or correcting genetic mutations linked to various diseases and cancers. The ability to predict RNA folding from sequence alone enables predictive screening and optimization without heavy reliance on experimental trial-and-error.

Associate Professor Ando emphasizes the impact of this milestone: “Reproducing the overall folding of basic stem-loop structures with such accuracy marks a new era in the computational exploration of RNA biology. These methods empower scientists to probe not just static structures, but also the dynamic behaviors integral to RNA function. I anticipate expanding applications from molecule design to drug discovery soon.” This study sets a robust computational benchmark, inspiring future innovations that will deepen our molecular understanding and therapeutic targeting of RNA.

The combination of atomistic force fields with efficient implicit solvent models, as demonstrated in this study, offers a promising path forward for molecular simulations. Expanding simulation libraries to include broader RNA classes and refining solvent models will be crucial next steps. Collaborations integrating experimental data and machine learning methodologies could also accelerate improvements, yielding more reliable, scalable simulations to decode the RNA folding code comprehensively.

In summary, through computational ingenuity and rigorous validation, Associate Professor Tadashi Ando’s research marks a transformative leap in modeling RNA folding. The ability to simulate complex RNA stem loops accurately from unfolded states unlocks the potential for high-resolution mechanistic understanding and innovative RNA-based therapeutics, heralding a new chapter in molecular biology and biomedicine.

Subject of Research:
Not applicable

Article Title:
Molecular Dynamics Simulations of RNA Stem-Loop Folding Using an Atomistic Force Field and a Generalized Born Implicit Solvent

News Publication Date:
26-Oct-2025

Web References:
https://pubs.acs.org/doi/10.1021/acsomega.5c05377

References:
DOI: 10.1021/acsomega.5c05377

Image Credits:
Associate Professor Tadashi Ando, Tokyo University of Science, Japan

Keywords:
Bioengineering, Biotechnology, Genetic material, RNA, Life sciences, Drug development, Drug design

Understanding the distinction between B-DNA and Z-DNA is crucial for comprehending the complexities of genetic regulation and cellular function. While B-DNA is the most prevalent form found in living organisms, Z-DNA has garnered attention for its unique structural properties and potential biological roles. Research indicates that Z-DNA may play a significant part in gene regulation, chromatin organization, and even the immune response. Thus, the ability to accurately predict Z-DNA forming regions within the genome is a significant advancement for genomic research.

Z-GENIE stands out for its accessibility, making sophisticated genomic analysis tools available at the fingertips of researchers, educators, and even casual enthusiasts. The R/Shiny interface provides an engaging platform that not only simplifies complex computational biology tasks but also encourages exploration and learning. This democratization of genomic technology is timely, as there is an increasing need for accessible bioinformatics tools in the scientific community.

At the core of Z-GENIE lies a robust algorithm that integrates a wealth of genomic data, including sequence motifs and structural features known to influence Z-DNA formation. By analyzing these data points, Z-GENIE can generate predictions about where Z-DNA formation is likely to occur within a given DNA sequence. This predictive capability is invaluable for researchers looking to pinpoint specific regions of interest for further experimental validation and study.

Engaging with Z-GENIE opens up a realm of possibilities for future research. For instance, scientists can utilize this resource to explore the genomic landscapes of specific organisms, potentially revealing how Z-DNA formation impacts evolutionary processes. Such insights could lead to a better understanding of the roles of Z-DNA in various cellular contexts and diseases, including cancer, where aberrant DNA structures have been shown to play a pivotal role.

Furthermore, the tool’s user-friendly design is an essential feature, as it lowers the barrier to entry for those who may not have extensive computational backgrounds. With interactive visualizations and step-by-step guidance, users can navigate the complexities of genomic analysis with ease. This feature fosters collaboration among researchers who can share insights and findings more readily, promoting a culture of transparency and innovation within genomic research.

Z-GENIE is not merely a predictive tool; it is a catalyst for hypothesis generation. By revealing potential Z-DNA regions, researchers can formulate new questions regarding gene expression, DNA repair mechanisms, and the influence of Z-DNA structures on chromatin dynamics. Consequently, the implications of this research extend beyond Z-DNA itself, as the findings may influence broader genomic understanding and applications in synthetic biology and genetic engineering.

User feedback has already started pouring in, demonstrating the enthusiasm and excitement surrounding Z-GENIE. Researchers have reported successful applications of the tool in their projects, underscoring its utility in real-world research settings. Academic institutions and laboratories are recognizing the potential for Z-GENIE to enhance their studies, facilitate collaborative efforts, and accelerate discoveries in the genetic realm.

Challenges remain in the field of predicting complex higher-order structures in DNA. While Z-GENIE offers a powerful tool for Z-DNA prediction, ongoing research will be required to fine-tune its algorithms and expand its capabilities. As the scientific community engages with this resource, iterative improvements and refinements are anticipated, further enhancing its predictive power and reliability.

Genomic prediction is an exciting frontier, and tools like Z-GENIE are set

Circular RNAs (circRNAs) are a unique class of endogenous non-coding RNAs characterized by their covalently closed loop structures. Unlike linear RNAs, circRNAs lack 5′ caps and 3′ poly-A tails, thereby conferring them with remarkable stability. Recently, circRNAs have emerged as vital players in gene regulation across numerous pathophysiological contexts, including oncogenesis. In bladder cancer, a malignancy arising from the urothelial lining of the urinary bladder, aberrant circRNA expression profiles have been implicated in tumor progression, metastasis, and therapeutic resistance.

The retracted article sought to elucidate the function of circfarsa, a specific circRNA, in modulating oncogenic pathways through its interaction with microRNA-330-5p (miR-330-5p). MicroRNAs (miRNAs) are short, non-coding RNA molecules that regulate gene expression post-transcriptionally by binding target mRNAs, leading to their degradation or translational inhibition. The concept of circRNAs acting as “microRNA sponges” — sequestering miRNAs and preventing them from downregulating target mRNAs — has revolutionized understanding of RNA-based regulatory networks in cancer.

Through the lens of this research, circfarsa was hypothesized to act as a molecular sink for miR-330-5p within bladder cancer cells, effectively attenuating the tumor-suppressive functions of this microRNA. miR-330-5p itself has been documented in various malignancies for its ability to modulate cell proliferation, apoptosis, and invasion, rendering it an attractive target for therapeutic manipulation.

The initial findings proposed that circfarsa sequestration of miR-330-5p enhanced the malignant phenotype of bladder cancer cells by derepressing oncogene expression. This mechanistic insight suggested novel intervention points, potentially guiding the development of RNA-based therapeutics aimed at disrupting the circfarsa/miR-330-5p axis to inhibit tumor growth and dissemination.

However, subsequent re-examination of experimental data and methodological approaches led the authors to retract their conclusions. While no specific incidents have been publicly detailed, retractions in molecular oncology frequently arise from incomplete reproducibility, lack of sufficient controls, or data misinterpretation undermining the validity of conclusions. This cautious retrenchment underscores the complexities inherent in dissecting intricate RNA regulatory networks, where subtle technical nuances critically influence results.

The bladder cancer research field is particularly sensitive to such developments, given the pressing need for reliable biomarkers and novel therapeutic targets. Bladder cancer remains one of the most prevalent urological malignancies worldwide, with high recurrence rates and variable treatment responses. Insight into RNA-mediated gene regulation continues to hold promise for addressing these clinical challenges.

The retraction also serves as a reminder of the evolving nature of scientific knowledge and the responsibilities of researchers to maintain transparency and scientific integrity. As the molecular oncology community continues to unravel circRNA functionalities, stringent experimental designs and independent validations are paramount to avoid premature translational applications that could misdirect clinical strategies.

Notably, circRNAs like circfarsa are still an active area of interest beyond this particular study. Advances in high-throughput sequencing technologies and bioinformatics have accelerated circRNA discovery, revealing complex networks influencing cellular phenotypes. The sponge function of circRNAs constitutes only one facet of their diverse biological roles, which also encompass transcriptional regulation, protein scaffolding, and modulation of alternative splicing.

Future investigations into the circfarsa-miR-330-5p interaction will necessitate enhanced methodological rigor, incorporating orthogonal validation techniques such as RNA immunoprecipitation, luciferase reporter assays, and in vivo functional models. Clarifying the contextual dependencies and temporal dynamics of these molecules in bladder cancer will be crucial to discern their genuine therapeutic relevance.

This episode accentuates the imperative for open data sharing and collaborative efforts across laboratories to verify findings with independent cohorts and platforms. The scientific community’s ability to self-correct is instrumental in safeguarding the trustworthiness of biomedical literature and ultimately advancing patient care.

In sum, while the retraction signifies a setback for the proposed model of circfarsa’s role as a miR-330-5p sponge in bladder cancer, it concurrently provides a valuable checkpoint. It spotlights the challenges posed by emerging RNA biology in oncogenesis, encouraging more nuanced approaches to validate mechanistic insights. The pursuit of RNA-centric cancer therapies remains vigorous, bolstered by continual technological innovation and critical appraisal.

As bladder cancer research accelerates, dissecting the multilayered regulatory circuits involving circRNAs and miRNAs will undoubtedly transform understanding of tumor biology. Harnessing these molecular frameworks holds transformative potential for precision oncology, contingent on replicable science and rigorous validation. The scientific vigilance exemplified by this retraction ultimately strengthens the foundation for breakthroughs that may reshape bladder cancer management in the future.

Subject of Research: The regulatory interaction between the circular RNA circfarsa and microRNA-330-5p in bladder cancer cells.

Article Title: Retraction Note: The circular RNA circfarsa sponges microRNA-330-5p in tumor cells with bladder cancer phenotype.

Article References: Fang, C., Huang, X., Dai, J. et al. Retraction Note: The circular RNA circfarsa sponges microRNA-330-5p in tumor cells with bladder cancer phenotype. BMC Cancer 25, 1613 (2025). https://doi.org/10.1186/s12885-025-15198-2

Image Credits: Scienmag.com

The core of the PB-DiffHiC framework lies in its sophisticated statistical modeling designed to enhance the analysis of chromatin interactions. Historically, the study of chromatin has been hampered by limitations in resolution and sensitivity when analyzing high-throughput data. High-resolution Hi-C techniques, which map the spatial organization of the genome, generate an enormous amount of data, but extracting biologically relevant insights from this data remains challenging. The PB-DiffHiC model addresses these issues, providing a robust statistical toolkit that can cope with the complexity of genomic data while providing reliable results.

What makes PB-DiffHiC particularly exciting is its ability to identify differences in chromatin interactions across different conditions or cell types. Traditional methods often overlook subtle yet biologically significant changes, but the new framework is engineered to detect these nuanced variations within complex datasets. By leveraging a pseudo-bulk approach, the researchers maximize the utility of available data, resulting in enhanced power to distinguish true biological differences from noise—a critical challenge in genomic analysis.

In the study, Zhou and colleagues applied the PB-DiffHiC framework to a variety of datasets, demonstrating its versatility and efficacy. They offer compelling examples illustrating how the framework not only improves detection rates of differential interactions but also refines our understanding of the underlying biological processes. For instance, by applying the PB-DiffHiC tool to cancer cell lines, the researchers could pinpoint chromatin interaction shifts that correlate with malignant transformation, shedding light on potential new therapeutic targets.

Moreover, the framework includes user-friendly features tailored for researchers with varying levels of statistical expertise. By providing intuitive visualizations and interpretations of results, PB-DiffHiC serves as an accessible tool for scientists from various disciplines. This democratization of advanced statistical methods in genomic research signals a shift toward more inclusive scientific inquiry, allowing researchers to harness the power of advanced analytics without needing extensive training in statistics.

As the scientific community navigates the complexities of epigenetic regulation, the introduction of PB-DiffHiC is poised to significantly reshape our approach to studying chromatin dynamics. Understanding how chromatin structure influences gene expression could pave the way for novel approaches to disease prevention and treatment. The ramifications of this research extend to fields such as developmental biology, neuroscience, and immunology, where chromatin organization plays a pivotal role in cell identity and functional capacity.

In addition, the implications of the PB-DiffHiC framework extend to agricultural and environmental sciences. As researchers seek to understand the genetic basis of traits in crops or the response of organisms to environmental stressors, the ability to discern differential chromatin interactions offers a powerful avenue for discovery. The potential to improve crop resilience or yield through genetic manipulation becomes increasingly feasible with such advanced tools at our disposal.

The adoption of PB-DiffHiC could also catalyze further innovations in the field of genomics. With the demand for high-resolution data analysis growing, tools like PB-DiffHiC are vital for translating raw data into actionable biological insights. Through collaboration and continued refinement of these methodologies, scientists can expand our understanding of genetic regulation and its pervasive impact on health and disease.

Future studies employing the PB-DiffHiC framework could offer insights into the long-term dynamics of chromatin interactions across development or in response to therapy, providing a rich avenue for exploration. As researchers grapple with the intricate web of regulatory elements within the genome, the capabilities of PB-DiffHiC may prove essential for unlocking the code of genetic expression. Cross-disciplinary collaboration will be key to maximizing the framework’s potential, as experts in computational biology, statistics, and genetics come together to tackle complex biological questions.

As science continues to advance, the research community stands at the forefront of a genomics revolution. Zhou et al.’s development of the PB-DiffHiC framework positions researchers to explore the unexplored territories of chromatin interactions with newfound clarity. This is not merely a scientific advancement—it’s a message of hope for many patients who are waiting for breakthroughs in therapies derived from a deeper understanding of genetics.

The incorporation of such comprehensive tools into routine research practices can lead to more consistent and reproducible results, a necessity in the pursuit of scientific rigor. With a commitment to embracing innovative methodologies like PB-DiffHiC, the field of genomics is poised for an exciting era of discovery, where data holds the key to understanding life’s most fundamental processes.

In summary, PB-DiffHiC represents a major leap forward in chromatin research, allowing for the detection of subtle alterations that could have significant biological implications. As this framework gains traction, its contributions will likely shape the next generation of genomic research, leading to transformational breakthroughs across scientific disciplines. The potential for PB-DiffHiC to uncover the mysteries of chromatin interactions is vast, and its impact on science and medicine promises to be extensive.

Subject of Research: Differential Chromatin Interactions

Article Title: PB-DiffHiC: a statistical framework for detecting differential chromatin interactions from high resolution pseudo-bulk Hi-C data

Article References:

Zhou, Y., Hu, Y., Tan, L. et al. PB-DiffHiC: a statistical framework for detecting differential chromatin interactions from high resolution pseudo-bulk Hi-C data.
BMC Genomics 26, 900 (2025). https://doi.org/10.1186/s12864-025-11987-y

Image Credits: AI Generated

DOI: 10.1186/s12864-025-11987-y

Keywords: chromatin interactions, PB-DiffHiC, high-resolution Hi-C, genomic research, statistical framework, gene regulation, cancer, statistical modeling, epigenetics, data analysis.